Imatinib Sandoz

Imatinib mesilate, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor and other KIT‑positive solid tumors.

GNH USA supplies Imatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib Sandoz is a tyrosine kinase inhibitor used in hematologic malignancies and selected solid tumors.

- Chronic Myeloid Leukemia (CML): achieves durable cytogenetic and molecular remission. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): provides targeted disease control. - Gastrointestinal Stromal Tumor (GIST): induces tumor shrinkage and prolongs progression‑free survival. - KIT‑positive solid tumors: offers targeted inhibition of KIT‑driven growth.

Imatinib may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral fluid retention. - Fatigue: general tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Neutropenia: low white‑blood‑cell count increasing infection risk. - Cardiac failure: reduced heart function, especially in patients with pre‑existing disease.

Before and during treatment, clinicians should monitor several safety parameters. - Monitor liver function: perform baseline and periodic liver‑enzyme tests. - Assess cardiac status: evaluate ejection fraction prior to therapy and during treatment. - Avoid use in pregnancy: category D; discuss risks with a qualified health professional. - Use caution in elderly patients: increased susceptibility to toxicity. - Store at ambient temperature: keep in the original pack, protect from moisture.

Imatinib interacts with several medicines that may alter its exposure or efficacy.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Imatinib levels. - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce Imatinib effectiveness.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may affect absorption; separate dosing by at least 2 hours. - Warfarin: Imatinib can enhance anticoagulant effect; monitor INR closely. - Live attenuated vaccines: potential reduced efficacy; consider timing of vaccination.